D
Delpor develops long-acting injectable therapies for chronic central nervous system disorders, using its proprietary PROZOR and NANOPOR delivery platforms to enable once-yearly dosing. The approach aims to improve patient adherence in conditions such as schizophrenia and opioid use disorder.
Updated 3 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Delpor is a clinical-stage biopharmaceutical company developing long-acting drug delivery systems for chronic conditions. The company utilizes proprietary technologies like PROZOR and NANOPOR to create once-yearly injectable therapies. This focus aims to improve patient adherence for central nervous system disorders such as Schizophrenia and Opioid Use Disorder.